Question: A spike in which hormone(s) is/are responsible for promoting ovulation? (SELECT ALL THAT APPLY)

Answer Choices:\n\nA. Follicle stimulating hormone B. Luteinizing hormone C. Progesterone D. Inhibin

Answer:A. Follicle stimulating hormone, B. Luteinizing hormone

 

Question: SC is a 47-year-old postmenopausal female with a familial history of early onset breast cancer. She wishes to start preventative treatment with a risk reduction agent. Which of the following agents is an appropriate recommendation for SC at this time? SELECT ALL THAT APPLY

Answer Choices:\n\nA. Fulvestrant (Faslodex®) B. Raloxifene (Evista®) C. Tamoxifen (Nolvadex®) D. Epirubicin (Ellence®)

Answer:B. Raloxifene (Evista®), C. Tamoxifen (Nolvadex®)

 

Question: Based on the Women’s Health Initiative (WHI) sub-analysis of major adverse events, hormone therapy is most likely to be safest for which of the following patients?

Answer Choices:\n\nA. 73-year-old woman 21 years beyond menopause B. 58-year-old woman 4 years beyond menopause C. 56-year-old woman 12 years beyond menopause D. 62-year-old woman 8 years beyond menopause

Answer:B. 58-year-old woman 4 years beyond menopause

 

Question: Which of the following are true regarding hormonal control of bone remodeling? SELECT ALL THAT APPLY

Answer Choices:\n\nA. Hypercalcemia leads to increased PTH release B. Hypocalcemia leads to increased calcitonin release C. Hypocalcemia leads to increased PTH release D. Hypercalcemia leads to increased calcitonin release

Answer:C. Hypocalcemia leads to increased PTH release, D. Hypercalcemia leads to increased calcitonin release

 

Question: Which of the following contraceptive formulations is expected to have the greatest risk of VTE?

Answer Choices:\n\nA. Vaginal ring (NuvaRing®) B. Progestin Only Pill (POP) C. Transdermal patch (Xulane®) D. Combined Oral Contraceptive (COC)

Answer:C. Transdermal patch (Xulane®)

 

Question: What hormone is responsible for the growth of the endometrium during the proliferative phase?

Answer Choices:\n\nA. Progesterone B. Estrogen C. Follicle stimulating hormone D. Luteinizing hormone

Answer:B. Estrogen

 

Question: Which of the following is NOT a common side effect of letrozole?

Answer Choices:\n\nA. Neutropenia B. Hypercholesterolemia C. Menopause-like symptoms (hot flashes, vaginal dryness, etc.) D. Arthralgia/myalgia

Answer:A. Neutropenia

 

Question: Which of the following is the most likely method by which progestins elicit their contraceptive action?

Answer Choices:\n\nA. Preventing mid-menstrual cycle LH and FSH peaks B. Acting as an estrogen antagonist in the ovary C. Inhibiting release of estrogen by the corpus luteum D. Increasing mid-menstrual cycle release of GnRH

Answer:A. Preventing mid-menstrual cycle LH and FSH peaks

 

Question: The primary purpose of administering bazedoxifene as a component of hormone therapy in menopause is to:

Answer Choices:\n\nA. Increase the efficacy of estrogenic activity in breast tissue B. Minimize the occurrence of tissue specific adverse effects associated with estrogen therapy C. Act as an estrogen agonist in endometrial tissue D. Minimize the occurrence of tissue specific adverse effects associated with progestin therapy

Answer:B. Minimize the occurrence of tissue specific adverse effects associated with estrogen therapy

 

Question: Which of the following most accurately describes the drug information change(s) enacted by the FDA “Pregnancy and Lactation Labeling Rule” (PLLR)?

Answer Choices:\n\nA. Implementation of a standardized rating system to classify safety/risk of drug use in lactation B. Updated FDA pregnancy letter categories to provide more precise descriptions of safety/risk information C. Reorganization of pregnancy and lactation information in official product labeling, with an added section for reproductive risk/safety D. Standardization of pregnancy and lactation safety/risk information in official product labeling and tertiary drug information resources

Answer:C. Reorganization of pregnancy and lactation information in official product labeling, with an added section for reproductive risk/safety

 

Question: What would a woman experience if she had normal prolactin levels, but no oxytocin?

Answer Choices:\n\nA. No milk production, but normal milk ejection B. Normal milk production and normal milk ejection C. No milk production and no milk ejection D. Normal milk production, but no milk ejection

Answer:D. Normal milk production, but no milk ejection

 

Question: If a company employs the gross method of recording accounts receivable from customers, then sales discounts taken should be reported as

Answer Choices:\n\nA. sales discounts forfeited on the income statement B. a deduction from sales revenue on the income statement C. an increase to sales revenue on the income statement D. an item of “other income and expense” on the income statement

Answer:B

 

Question: Provide three (3) counseling points for a patient starting alendronate (Fosamax®). List the 3 items, separated by a comma, in the single blank below:

Answer Choices:\n\n(Free response)

Answer:Take on an empty stomach with a full glass of water, remain upright for at least 30 minutes, do not eat or drink anything else for 30 minutes

 

Question: A 21-year-old woman comes to the pharmacy for a refill of her combined oral contraceptive (COC), TriNessa® (norgestimate/ethinyl estradiol). She has been taking the contraceptive for 4 months and is complaining of increased acne and weight gain. She says the weight gain is not related to her monthly cycles. Which of the following recommendations is most appropriate to address the patient’s complaints at this time?

Answer Choices:\n\nA. Change to a COC with decreased progestin and androgen activity B. Change to a COC with increased progestin and androgen activity C. Change to a COC with increased progestin activity D. Change to a COC with decreased androgen activity E. No change; wait to see if the complaints resolve with continued use

Answer:A. Change to a COC with decreased progestin and androgen activity

 

Question: When treating symptoms of menopause, a progestogen is generally administered in order to offer:

Answer Choices:\n\nA. Protection of the endometrium B. Protection from breast cancer C. Protection of the ovaries D. Protection from osteoporosis

Answer:A. Protection of the endometrium

 

Question: Both acute and dose-related chronic cardiotoxicity are adverse effects most commonly associated with:

Answer Choices:\n\nA. Cyclophosphamide B. Capecitabine (Xeloda®) C. Paclitaxel (Taxol®) D. Doxorubicin (Adriamycin®)

Answer:D. Doxorubicin (Adriamycin®)

 

Question: During which hormonal period of the average woman’s uterine cycle is a woman most fertile?

Answer Choices:\n\nA. Low levels of progesterone, and high levels of estrogen B. Low levels of progesterone, and low levels of estrogen C. High levels of progesterone, and high levels of estrogen D. High levels of progesterone, and low levels of estrogen

Answer:A. Low levels of progesterone, and high levels of estrogen